Betterlife Pharma Inc. (BETRF)

[JohnCM]

Our Product Development Initiatives



Our product development initiatives will address unmet medical needs in health care.



PRODUCT



DELIVERY

TECHNOLOGY



INDICATION



GLOBAL

MARKET SIZE (1)



ESTIMATED

PRODUCT

LAUNCH

PGS-N001



Solmic Solubilisate / Oral



Cancer supportive care (CINV) (chemo-induced nausea and vomiting)



>$1B



2018

PGS-N002



Solmic Solubilisate / Oral



Restless leg syndrome



>$2B



2018

PGS-N003



Solmic Solubilisate / Oral



Pain and inflammation (for opioid withdrawal)



>$15B



2018

PGS-N004



Solmic Solubilisate / Oral



Cancer supportive care (mucositis relief)



>$12B



2018

PGS-N005



BiPhasix / Topical



Female sexual dysfunction (HSDD) (hypoactive sexual desire disorder)



>$6B



2019

PGS-N006



BiPhasix / Topical



Pain and inflammation (joints/opioid withdrawal)



>$20B



2018

PGS-N007



BiPhasix / Topical



Dermatology (skin irritation/redness/ itching)



>$13B



2018

PGS-N008



BiPhasix / Topical



Eye disease (glaucoma, intra-ocular pressure)



>$3B



2019

PGS-N009



Thrudermic / Topical



Pain and inflammation (opioid withdrawal)



>$15B



2018

PGS-N010



Solmic Solubilisate / Oral



Migraine (nausea, vomiting, dizziness, sensitivity to light, sounds and smells)



>$10B



2019